News

Explore the science, stories, and breakthroughs shaping regenerative pet care.

Gallant in the News News Release Interviews

Gallant in the News

TechCrunch Spotlights Gallant’s Breakthrough Approach to Pet Stem Cell

dvm360 Reports on Gallant’s Platform and Path Toward FDA-Labeled Therapies

BioProcess Insider Covers Gallant’s $18M Raise and Manufacturing Expansion

PetVet Magazine Publishes Feature by Dr. Linda Black on the Rise of Ready-to-Use Stem Cell Therapies

Veterinary Practice’s Innovation Feature for February 2024 Covers FCGS Study

dvm360 Covers Aaron Schacht’s Appointment to Gallant Board

News Release

Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market

Gallant Names Dr. Rebecca Windsor Director of Veterinary Affairs as Company Advances Its Off-the-Shelf Stem Cell Therapy for Cats

Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of “Off-the-Shelf” Stem Cell Therapies for Pets

Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis

Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)

Interviews

Gallant CEO Dr. Linda Black Joins The Bird Bath to Discuss $18M Series B and the Future of Regenerative Medicine

The People of Animal Health Cover

The People of Animal Health: Episode #41 – Dr. Linda Black

Veterinary Innovation Podcast Thumbnail

Veterinary Innovation Podcast: ‘Off-the-Shelf’ Stem Cell Therapies in Veterinary Care

VETgirl

VETgirl: Should I Pursue Research in Veterinary Medicine with Dr. Linda Black

My Veterinaty Life Thumbnail

My Veterinary Life: From Colics to Cures: Dr. Linda Black’s Mission to Transform Veterinary Medicine

Vet Life Reimagined

Vet Life Reimagined: Stem Cells to Leadership with Gallant’s CEO, Dr. Linda Black

Gallant in the News

TechCrunch Spotlights Gallant’s Breakthrough Approach to Pet Stem Cell

dvm360 Reports on Gallant’s Platform and Path Toward FDA-Labeled Therapies

BioProcess Insider Covers Gallant’s $18M Raise and Manufacturing Expansion

PetVet Magazine Publishes Feature by Dr. Linda Black on the Rise of Ready-to-Use Stem Cell Therapies

Veterinary Practice’s Innovation Feature for February 2024 Covers FCGS Study

dvm360 Covers Aaron Schacht’s Appointment to Gallant Board

News Release

Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market

Gallant Names Dr. Rebecca Windsor Director of Veterinary Affairs as Company Advances Its Off-the-Shelf Stem Cell Therapy for Cats

Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of “Off-the-Shelf” Stem Cell Therapies for Pets

Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis

Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)

Interviews

Gallant CEO Dr. Linda Black Joins The Bird Bath to Discuss $18M Series B and the Future of Regenerative Medicine

The People of Animal Health Cover

The People of Animal Health: Episode #41 – Dr. Linda Black

Veterinary Innovation Podcast Thumbnail

Veterinary Innovation Podcast: ‘Off-the-Shelf’ Stem Cell Therapies in Veterinary Care

VETgirl

VETgirl: Should I Pursue Research in Veterinary Medicine with Dr. Linda Black

My Veterinaty Life Thumbnail

My Veterinary Life: From Colics to Cures: Dr. Linda Black’s Mission to Transform Veterinary Medicine

Vet Life Reimagined

Vet Life Reimagined: Stem Cells to Leadership with Gallant’s CEO, Dr. Linda Black

Gallant is redefining veterinary medicine with ready-to-use stem cell therapies that reduce inflammation, restore function, and fit seamlessly into everyday practice.

© 2019-2025 Gallant. All Rights Reserved.
Terms & Conditions. Privacy Policy. Copyright & Cookies.